Prevention and treatment of dyslipidemia should therefore be considered as an integral part
of individual cardiovascular prevention interventions, which should be addressed primarily to
those at higher risk who will benefit most. Statins are the most commonly used options for
the pharmacologic treatment of dyslipidemia. In recent decades, numerous clinical trials have
demonstrated the efficacy of these drugs to reduce cardiovascular mortality and major non-fatal
atherothrombotic events in heterogeneous populations through both primary and secondary
prevention. This group of drugs is part of the recommendations of both US and European
guidelines, and should be prescribed to all patients who have already had a cardiovascular
event and have no specific contraindication. However, a large percentage of patients that
would benefit from a statin treatment do not receive them, have been prescribed a low dose
or for a limited time.
Arocha-Rodulfo, I. (2019). Estatinas, drogas de amplio espectro de acción y beneficios. Revista Hospital Clínico Universidad De Chile, 30(3). https://doi.org/10.5354/2735-7996.2019.70039
